Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;3(1):43-52.
doi: 10.1177/1758834010388342.

Balancing the efficacy and toxicity of chemotherapy in colorectal cancer

Michael S Braun  1 , Matthew T Seymour
Affiliations

Balancing the efficacy and toxicity of chemotherapy in colorectal cancer

Michael S Braun et al. Ther Adv Med Oncol. 2011 Jan.

Abstract

As the therapeutic options for the treatment of colorectal cancer have expanded over the past 20 years, so has the complexity of decision making. The goals of treatment in the palliative, adjuvant and neoadjuvant settings vary and it is not only the efficacy of drugs that influence treatment decisions. Age, performance status, the presence of significant comorbidities and the different treatment regimens and strategies provide medical oncologists with an array of options to attempt to maximize patients' quality of life and longevity.

Keywords: colorectal cancer; combination chemotherapy; fluorouracil; irinotecan; oxaliplatin; performance status; staged chemotherapy; toxicity; treatment breaks.

PubMed Disclaimer

References

    1. Adams R.A., Meade A.M., Madi A., Fisher D., Kay E., Kenny S., et al. (2009a) Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 100(2): 251–258 - PMC - PubMed
    1. Adams R., Wilson R., Seymour M.T., Meade A.M., Madi A., Cassidy J., et al. (2009b) Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: A randomised non-inferiority trial (MRC COIN). Eur J Cancer 7(Suppl): 10–10
    1. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10): 1626–1634 - PubMed
    1. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23): 2343–2351 - PubMed
    1. Andre T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et al. (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19): 3109–3116 - PubMed